Detecting Liver Cancer Using Cell-Free DNA Fragmentomes
Authors:
- Zachariah H. FodaZFZachariah H. Foda
- Akshaya V. AnnapragadaAAAkshaya V. Annapragada
- Kavya BoyapatiKBKavya Boyapati
- Daniel C. BruhmDBDaniel C. Bruhm
- Nicholas A. VulpescuNVNicholas A. Vulpescu
- Jamie E. MedinaJMJamie E. Medina
- Dimitrios MathiosDMDimitrios Mathios
- Stephen CristianoSCStephen Cristiano
- Noushin NiknafsNNNoushin Niknafs
- Harry T. LuuHLHarry T. Luu
- Michael G. GogginsMGMichael G. Goggins
- Robert A. AndersRARobert A. Anders
Top Cited Papers
Open Access
- 18 November 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (3) , 616-631
Abstract
Liver cancer is a major cause of cancer mortality worldwide. Screening individuals at high risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved survival, but current screening methods are inadequate. In this study, we used whole-genome cell-free DNA (cfDNA) fragmentome analyses to evaluate 724 individuals from the United States, the European Union, or Hong Kong with hepatocellular carcinoma (HCC) or who were at average or high-risk for HCC. Using a machine learning model that incorporated multifeature fragmentome data, the sensitivity for detecting cancer was 88% in an average-risk population at 98% specificity and 85% among high-risk individuals at 80% specificity. We validated these results in an independent population. cfDNA fragmentation changes reflected genomic and chromatin changes in liver cancer, including from transcription factor binding sites. These findings provide a biological basis for changes in cfDNA fragmentation in patients with liver cancer and provide an accessible approach for noninvasive cancer detection. Significance: There is a great need for accessible and sensitive screening approaches for HCC worldwide. We have developed an approach for examining genome-wide cfDNA fragmentation features to provide a high-performing and cost-effective approach for liver cancer detection. See related commentary Rolfo and Russo, p. 532. This article is highlighted in the In This Issue feature, p. 517Keywords
All Related Versions
Funding Information
- National Cancer Institute (CA121113)
- National Cancer Institute (CA006973)
- National Cancer Institute (CA233259)
- National Institute of General Medical Sciences (GM136577)
- National Cancer Institute (CA237624)
- National Cancer Institute (CA062924)
- National Institute on Drug Abuse (DA036297)
- National Institute on Drug Abuse (DA012568)
- DOD Peer Reviewed Cancer Research Program (W81XWH-20-1-0605)
- Stand Up To Cancer (SU2C -AACR -DT1415)
- Stand Up To Cancer (SU2C-AACR-DT23-17)
This publication has 61 references indexed in Scilit:
- Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patientsAnalytical Biochemistry, 2013
- Hepatocellular Carcinoma: Focus on Different Aspects of ManagementISRN Oncology, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic ReviewJournal of General Internal Medicine, 2012
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011
- Oncogenetic tree modeling of human hepatocarcinogenesisInternational Journal of Cancer, 2011
- Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paperInternational Journal of Cancer, 2010
- BEDTools: a flexible suite of utilities for comparing genomic featuresBioinformatics, 2010
- Randomized controlled trial of screening for hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2004
- Hepatitis C and hepatocellular carcinomaHepatology, 1997